SCHEMBL4619478

SCHEMBL4619478

OC[C@H](O)COc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.62
MAPK1 P28482 1/20 0.62
LMNA P02545 3/20 0.61
CYP2D6 P10635 3/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
ADRB2 P07550 1/20 0.58
ADRB1 P08588 1/20 0.58
ADRB3 P13945 1/20 0.58
CYP1A2 P05177 3/20 0.56
KDM4E B2RXH2 3/20 0.56
AGTR1 P30556 1/20 0.56
MAPT P10636 2/20 0.55
HTT P42858 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
HIF1A Q16665 1/20 0.54
RECQL P46063 1/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
CYP2C19 P33261 1/20 0.53
AR P10275 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6480727 1.00 TSHR (0.62) TSHRMAPK1LMNACYP2D6L3MBTL1
SCHEMBL117951 1.00 TSHR (0.62) TSHRMAPK1LMNACYP2D6L3MBTL1
Bicarbonate SCHEMBL27926288 0.94 TSHR (0.57) TSHRMAPK1LMNACYP2D6L3MBTL1
SCHEMBL1496800 0.92 TSHR (0.56) TSHRMAPK1LMNACYP2D6L3MBTL1
SCHEMBL8994531 0.92 TSHR (0.56) TSHRMAPK1LMNACYP2D6L3MBTL1
Ether SCHEMBL9517511 0.89 TSHR (0.57) TSHRMAPK1LMNACYP2D6L3MBTL1
SCHEMBL267463 0.89 LMNA (0.68) TSHRLMNACYP2D6L3MBTL1ADRB2
SCHEMBL6228324 0.89 AR (0.61) TSHRMAPK1LMNACYP2D6CYP1A2
SCHEMBL11455057 0.88 KDM1A (0.57) TSHRMAPK1LMNACYP1A2KDM4E
Nitric Acid SCHEMBL9874923 0.88 MEN1 (0.53) TSHRMAPK1LMNACYP2D6L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080213833-A1 Methods for Obtaining Optically Active Glycidyl Ethers and Optically Active Vicinal Diols from Racemic Substrates OXRANE (UK) LTD. (GB) 2008-09-04 US disclosed
EP-1885849-A2 METHODS FOR OBTAINING OPTICALLY ACTIVE GLYCIDYL ETHERS AND OPTICALLY ACTIVE VICINAL DIOLS FROM RACEMIC SUBSTRATES Oxyrane UK Limited (GB) 2008-02-13 EP disclosed
WO-2006109198-A2 METHODS FOR OBTAINING OPTICALLY ACTIVE GLYCIDYL ETHERS AND OPTICALLY ACTIVE VICINAL DIOLS FROM RACEMIC SUBSTRATES OXYRANE UK LIMITED (GB) 2006-10-19 WO disclosed
EP-1175379-B1 METHOD FOR THE ASYMMETRIC DIHYDROXYLATION OF OLEFINS, USING OSMIUM CATALYSTS BAYER CHEMICALS AG (DE) 2004-01-02 EP disclosed
EP-1175379-A1 METHOD FOR THE ASYMMETRIC DIHYDROXYLATION OF OLEFINS, USING OSMIUM CATALYSTS Bayer Aktiengesellschaft (DE) 2002-01-30 EP disclosed
WO-2000064844-A1 METHOD FOR THE ASYMMETRIC DIHYDROXYLATION OF OLEFINS, USING OSMIUM CATALYSTS BAYER AKTIENGESELLSCHAFT (DE) 2000-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080213833-A1 Methods for Obtaining Optically Active Glycidyl Ethers and Optically Active Vicinal Diols from Racemic Substrates GALE, DERA, GNE TSHR 4775/4885MAPK1 3231/4885LMNA 2892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.